Shots:
Hanmi Pharm has granted Eli Lilly exclusive global rights (excl. Korea) to develop, manufacture & commercialize sonefpeglutide, a GLP-2 analog incorporating Hanmi's long-acting platform tech, Lapscovery
As per the deal, Hanmi will receive $75M upfront & up to $1.185B in clinical development, regulatory approval, and commercialization milestone payments, with royalties following product launch
Hanmi…
